Researchers with the Age-Related Eye Disease Study (AREDS) reported in 2001 that a nutritional supplement called the AREDS formulation can reduce the risk of developing advanced age-related macular degeneration (AMD). The original AREDS formulation contains vitamin C, vitamin E, beta-carotene, zinc and copper.*
AREDS2 was a multi-center randomized trial designed to assess the effects of oral supplementation of high doses of macular xanthophylls (lutein and zeaxanthin) and/or omega -3 LCPUFAs (DHA and EPA) for the treatment of AMD and cataract. All participants were offered additional treatment with the study formulation used in AREDS. For those who elected to take this additional supplement, which is now considered the standard of care, further randomization occurred to evaluate the possibility of deleting beta-carotene and decreasing the original levels of zinc in the formulation for the treatment of AMD, if consent was obtained.*
What do each of the AREDS 2 Ingredients do?
National Eye Institute
U.S. National Institutes of Health
*This statement above has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.